Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ITCI
- Price
- 131.87
- Stock movement down
- -0.05 (-0.04%)
- Company name
- Intracellular Th
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 13.98B
- Ent value
- 13.70B
- Price/Sales
- 22.81
- Price/Book
- 12.21
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 553.38
- PEG
- -
- EPS growth
- -12.47%
- 1 year return
- 90.56%
- 3 year return
- 29.46%
- 5 year return
- 53.39%
- 10 year return
- 17.34%
Last updated: 2025-04-11
DIVIDENDS
ITCI does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 22.81 |
| Price to Book | 12.21 |
| EV to Sales | 22.35 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 106.02M |
| EPS (TTM) | -0.82 |
| FCF per share (TTM) | -0.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 612.92M |
| Gross profit (TTM) | 565.66M |
| Operating income (TTM) | -121.62M |
| Net income (TTM) | -86.37M |
| EPS (TTM) | -0.82 |
| EPS (1y forward) | 0.24 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 92.29% |
| Operating margin (TTM) | -19.84% |
| Profit margin (TTM) | -14.09% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 464.31M |
| Net receivables | 145.61M |
| Total current assets | 1.27B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 16.02M |
| Total assets | 1.32B |
| Accounts payable | 10.34M |
| Short/Current long term debt | 17.71M |
| Total current liabilities | 166.11M |
| Total liabilities | 179.62M |
| Shareholder's equity | 1.14B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -62.16M |
| Capital expenditures (TTM) | 750.00K |
| Free cash flow (TTM) | -62.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -7.54% |
| Return on Assets | -6.52% |
| Return on Invested Capital | -7.49% |
| Cash Return on Invested Capital | -5.46% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 131.90 |
| Daily high | 131.98 |
| Daily low | 131.63 |
| Daily Volume | 16.0M |
| All-time high | 131.92 |
| 1y analyst estimate | 103.50 |
| Beta | 0.97 |
| EPS (TTM) | -0.82 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| ITCI | S&P500 | |
| Current price drop from All-time high | -0.04% | -8.48% |
| Highest price drop | -87.64% | -56.47% |
| Date of highest drop | 1 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -39.34% | -11.07% |
| Avg time to new high | 40 days | 12 days |
| Max time to new high | 1585 days | 1805 days |
COMPANY DETAILS
Marketcap
13.98B
Marketcap category
Large-cap
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Employees
610
Investor relations
-
SEC filings
CEO
Sharon Mates
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner